Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches
Само за регистроване кориснике
2023
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it’s used for precise mole...cular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML.
Кључне речи:
Acute myeloid leukemia / Immunotherapy / Pediatric / Targeted therapyИзвор:
Biochemical Pharmacology, 2023, 215, 115705-Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200042 (Универзитет у Београду, Институт за молекуларну генетику и генетичко инжењерство) (RS-MESTD-inst-2020-200042)
URI
https://www.sciencedirect.com/science/article/pii/S0006295223002964https://imagine.imgge.bg.ac.rs/handle/123456789/2103
Институција/група
Institut za molekularnu genetiku i genetičko inženjerstvoTY - JOUR AU - Tošic, Natasa AU - Marjanović, Irena AU - Lazić, Jelena PY - 2023 UR - https://www.sciencedirect.com/science/article/pii/S0006295223002964 UR - https://imagine.imgge.bg.ac.rs/handle/123456789/2103 AB - Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it’s used for precise molecular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML. T2 - Biochemical Pharmacology T1 - Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches SP - 115705 VL - 215 DO - 10.1016/j.bcp.2023.115705 ER -
@article{ author = "Tošic, Natasa and Marjanović, Irena and Lazić, Jelena", year = "2023", abstract = "Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric AML has improved over the last decades, with overall survival rates reaching up to 70%. Still, AML is among the leading types of pediatric cancers by its high mortality rate. Modulation of standard therapy, like chemotherapy intensification, hematopoietic stem cell transplantation and optimized supportive care, could only get this far, but for the significant improvement of the outcome in pediatric AML, development of novel targeted therapy approaches is necessary. In recent years the advances in genomic techniques have greatly expanded our knowledge of the AML biology, revealing molecular landscape and complexity of the disease, which in turn have led to the identification of novel therapeutic targets. This review provides a brief overview of the genetic landscape of pediatric AML, and how it’s used for precise molecular characterization and risk stratification of the patients, and also for the development of effective targeted therapy. Furthermore, this review presents recent advances in molecular targeted therapy and immunotherapy with an emphasis on the therapeutic approaches with significant clinical benefits for pediatric AML.", journal = "Biochemical Pharmacology", title = "Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches", pages = "115705", volume = "215", doi = "10.1016/j.bcp.2023.115705" }
Tošic, N., Marjanović, I.,& Lazić, J.. (2023). Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. in Biochemical Pharmacology, 215, 115705. https://doi.org/10.1016/j.bcp.2023.115705
Tošic N, Marjanović I, Lazić J. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches. in Biochemical Pharmacology. 2023;215:115705. doi:10.1016/j.bcp.2023.115705 .
Tošic, Natasa, Marjanović, Irena, Lazić, Jelena, "Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches" in Biochemical Pharmacology, 215 (2023):115705, https://doi.org/10.1016/j.bcp.2023.115705 . .